Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• van der Geest LG, Lam-Boer J, Koopman M, et al. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015;32(5):457–465.
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312.
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909–1919.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–1417.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25(7):1346–1355.
   PubMed Web of Science ®Google Scholar
• Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238(4):562–570.
   PubMed Web of Science ®Google Scholar
• Conradi LC, Styczen H, Sprenger T, et al. Frequency of HER-2 positivity in rectal cancer and prognosis. Am J Surg Pathol. 2013;37(4):522–531.
   PubMed Web of Science ®Google Scholar
• Li C, Liu DR, Ye LY, et al. HER-2 overexpression and survival in colorectal cancer: a meta-analysis. J Zhejiang Univ Sci B. 2014;15(6):582–589.
   PubMed Web of Science ®Google Scholar
• Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386(3):241–251.
   PubMed Web of Science ®Google Scholar
• Wu SW, Ma CC, Yang Y. The prognostic value of HER-2/neu overexpression in colorectal cancer: evidence from 16 studies. Tumour Biol. 2014;35(11):10799–10804.
   PubMedGoogle Scholar
• Kruszewski WJ, Rzepko R, Ciesielski M, et al. Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers. 2010;29(5):207–212.
   PubMed Web of Science ®Google Scholar
• Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1(6):508–523.
   PubMed Web of Science ®Google Scholar
• De Cuyper A, Van Den Eynde M, Machiels JP. HER2 as a predictive biomarker and treatment target in colorectal cancer. Clin Colorectal Cancer. 2020;19(2):65–72.
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20(4):518–530.
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial [published correction appears in Lancet Oncol. 2016 Oct;17 (10):e420]. Lancet Oncol. 2016;17(6):738–746.
   PubMed Web of Science ®Google Scholar
• Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22(6):779–789.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Xianhua F, Ying J, et al. Dual-targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: preliminary results from a multicenter phase 2 trial. J clin oncol. 2021;39(15_suppl):e15554–e15554.
   Web of Science ®Google Scholar
• Sartore-Bianchi A, Lonardi S, Martino C, et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open. 2020;5(5):e000911.
   PubMed Web of Science ®Google Scholar
• Pheneger T, Bouhana K, Anderson D, et al. In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. Cancer Res. 2009;69:1795.
   Google Scholar
• Frankel C, Palmieri FM. Lapatinib side-effect management. Clin J Oncol Nurs. 2010;14(2):223–233.
   PubMed Web of Science ®Google Scholar
• Lucchini E, Pilotto S, Spada E, et al. Targeting the epidermal growth factor receptor in solid tumors: focus on safety. Expert Opin Drug Saf. 2014;13(5):535–549.
   PubMed Web of Science ®Google Scholar
• Sandler AB. Nondermatologic adverse events associated with anti-EGFR therapy. Oncology. 2006 Apr;20(5 Suppl 2):35–40.
   PubMedGoogle Scholar
• Kulukian A, Lee P, Taylor J, et al. Preclinical activity of HER2-Selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther. 2020 Apr;19(4):976–987.
   PubMed Web of Science ®Google Scholar
• Lee P, Napier C, Garrus J, et al. Abstract #5581: in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB-2 in combination with trastuzumab or docetaxel in a BT-474 human breast carcinoma xenograft model. Cancer Res. 2009;69(9 Supplement):5581.
   Google Scholar
• Moulder SL, Borges VF, Baetz T, et al. Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2(+)-advanced solid tumors, with an expansion cohort in HER2(+) Metastatic Breast Cancer (MBC). Clin Cancer Res. 2017;23(14):3529–3536.
   PubMed Web of Science ®Google Scholar
• Borges VF, Ferrario C, Aucoin N, et al. Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: a phase 1b clinical trial. JAMA Oncol. 2018;4(9):1214–1220.
   PubMed Web of Science ®Google Scholar
• Murthy R, Borges VF, Conlin A, et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 Jul;19(7):880–888.
   PubMed Web of Science ®Google Scholar
• Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609.
   PubMed Web of Science ®Google Scholar
• Strickler JH, Zemla T, Ou F, et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial. Ann Oncol. 2019;30(suppl_5):v198–v252.
   Google Scholar